Medicines Management

Medicines management and older people
- a guide for healthcare professionals

Edited by
Ralph S Greenwall, BPharm (Hons)
Contents

1. Introduction 4
2. The ageing process and medication 5
3. Pharmacokinetics & pharmacodynamics: 8
   Drug absorption 8
   Drug distribution 9
   Drug metabolism 10
   Drug excretion 11
   Plasma concentration 11
   Therapeutic window 12
4. Oral medicines: 13
   Different types of oral formulations 13
   Tablets and capsules 13
   Different types of coatings and modifications 14
   Dose dumping 16
   Medication manipulation 17
   Liquid alternatives 18
5. Adverse drug reactions: 19
   Type A reactions 19
   Type B reactions 19
   Reporting ADRs 20
   When to report an ADR 20
   Common medication causes of adverse drug reactions in older people 21
   Clinical presentation of ADRs in older people 22
   Common medication causes of adverse drug reactions in older people - Cardiovascular system 23
   Common medication causes of adverse drug reactions in older people - central nervous system (CNS) 24
   Common medication causes of adverse drug reactions in older people - anti-inflammatory drugs 25
6. Medication and older people: 19
   Polypharmacy and cascade prescribing 26
   STOPP and START criteria 26
   Medication review 27
   Prescribing for older people 28
   Principles of medication management and older people 29
7. Compliance, concordance and adherence: 30
   Factors affecting adherence 31
8. Legal aspects of medication administration: 32
   Licensed and unlicensed medicines 32
   Medicines and the regulatory framework 32
   The Human Medicines Regulations 2012 32
   Health and Social Care Act 2008 and the Care Quality Commission (CQC) 33
   Equality Act 2010 33
   The Nursing & Midwifery Council (2008) Standards for Medicines Management 34
   Patient consent 34
   Negligence 35
9. Additional resources 36
10. Glossary of terminology 37
11. References 41
12. Notes 42
13. Biography 43
The UK has an increasingly ageing population. The average life expectancy is now over 80 years and predicted to rise to over 90 by 2035. The percentage of people aged 65 and over increased from 15 per cent in 1985 to 17 per cent in 2010, an increase of 1.7 million people. By 2035 it is projected that those aged 65 and over will account for 23 per cent of the total population.

Older people have a higher prevalence of illness and take around 50% of all prescribed medicines. Four in five people over 75 take at least one prescribed medicine, with 36% taking four or more medicines.

The medicines management of an older person is complicated by multiple diseases, complex medication regimes and the ageing process affecting the body’s capacity to handle medicines. In addition, medicines have become increasingly sophisticated, particularly in their delivery systems and there are legal aspects to consider as well as pharmacological ones.

The safe delivery of medicines for older people is a critical and challenging aspect of patient care. This booklet aims to help healthcare professionals learn more about how medication works (focusing particularly on oral medicines), how the ageing process affects medicines, common adverse drug reactions, the definitions of compliance and concordance as well as to give an overview of some of the legal aspects of medicines management.

Almost half of the NHS drugs bill is spent on medicines for older people and a core standard set out in the National Service Framework is to ‘ensure that this is spent in a clinical and cost effective manner, to maintain or improve the health of older people and not to increase the effects of existing illness.’

Key points from the NSF in relation to medication and older people are:
- As many as 50% of older people may not be taking their medicines as intended
- Dosage instructions on the medicine label are sometimes inadequate - such that neither patient nor carer has access to the correct dosage information, for example, “Take as directed” or “Take as required”
- Some medicines are under-used in older people. For example, anti-thrombotic treatments to prevent stroke, preventive treatment for asthma, and antidepressants
- Some long-term treatments can be successfully withdrawn - diuretic treatment, for example, can be stopped in about half of patients providing progress is monitored
- Many adverse reactions to medicines could be prevented

Liver function reduced
There are age-related changes that are known to affect liver function, for example reduction in the both total liver size and total blood flow. The total blood flow to the liver of a person aged 91 may reduce by up to 58% compared to when they were 24 years old.
Selecting the right formulation for this patient group can be as important as the treatment itself. If a patient is unable to swallow their medicines they are unlikely to take them. If the patient can swallow a liquid formulation safely and a suitable liquid or dispersible formulation is available then this may be the most appropriate solution. See http://www.swallowingdifficulties.com for a comprehensive list of liquid and non-oral alternatives to tablet or capsule formulations.

In a recent study, medication errors were three times more likely to occur when administering medicines to patients with dysphagia, than to patients with a normal swallowing function.

Always take extra care when giving medicines to people with swallowing difficulties.

The ageing process and medication (Continued)

The reduction in total liver size is likely to lead to a decrease in the levels of drug metabolizing enzymes. A further decrease in efficiency is likely to result from the reduction in liver blood flow, due to the decreased exposure of the drug to metabolising enzymes.

Renal impairment
The total size of the kidneys decreases with age, as does the number of functioning nephrons. There is also decreased renal blood flow with increasing age. This results in a progressive decrease in renal function. This problem is a combination of a fall-off in glomerular filtration rate and the propensity for dehydration in this age group. The mean glomerular filtration rate can fall from 140ml/min/1.73m² in a 30 year old to 97ml/min/1.73m² in an 80 year old.

Reduced GI motility
A number of age-related diseases can affect gastrointestinal motility in older people: for example, long-standing diabetes mellitus may reduce gastric emptying in up to 50% of patients; depression significantly prolongs gut transit times; hypothyroidism may prolong oro-caecal transit times; and chronic renal failure is associated with impaired gastric emptying. In addition, various frequently prescribed drugs can cause reduced gastrointestinal motility in older patients, including anticholinergics, opioid analgesics and calcium antagonists.

Changes in body composition
Altered plasma concentrations and individual body composition, in particular body fat and intracellular fluid content, can significantly influence drug distribution in older people. The decreased muscle and tissue mass that accompanies ageing will also influence the distribution of certain drugs, as will the reduced blood flow to tissues and organs. In addition, there is evidence that the blood brain barrier is less intact in older people which allows certain drugs to distribute into the brain in increased concentration.

Swallowing difficulties
The loss of muscle tone associated with ageing, together with a reduction in saliva production (xerostomia) can reduce the older person’s ability to swallow medicines in a solid dosage form. Dysphagia (difficulty in swallowing) is estimated to occur to some degree in 70-90% of the older population. Ageing is also associated with conditions which have the potential to cause dysphagia e.g. stroke and Parkinson’s disease. Therefore, before prescribing/administering any medication for an older person it is imperative that their ability to swallow the prescribed formulation is determined.
Whether administering or prescribing medication, it is essential to understand how drugs work and interact with the body. Two key processes need to be considered; pharmacodynamics which is the effect that drugs have on the body and pharmacokinetics which is the way drugs move round the body during absorption, distribution, metabolism and excretion.

**Pharmacokinetics**
what the body does to the drug

**Pharmacodynamics**
what the drug does to the body

When a medicine is administered, it is absorbed into the bloodstream and distributed round the body. The drug reaches a peak level and soon after this, the level falls steadily as it is metabolised and/or eliminated. This basic process happens with every medication.

The key stages that a drug undergoes on entering the body are summarised below:

**Absorption** - the process by which the drug enters the bloodstream
**Distribution** - where the drug goes in the body after absorption
**Metabolism** - breakdown of the drug by the body
**Excretion or elimination** - where the drug or metabolites leave the body

**Drug absorption**
When a drug has been administered orally, it passes into the stomach and then into the intestines. During this time, the drug is absorbed into the bloodstream.

**Effect of food on drug absorption**
Both the rate of absorption and the amount of drug that is actually absorbed are affected by the presence or absence of food in the gastro intestinal (GI) tract. For example, a large meal taken at the same time as some medicines may slow the progress of a drug through the GI system and reduce the rate of drug absorption. Some foods are known specifically to reduce drug absorption; large amounts of protein reduce the absorption of levodopa and calcium rich foods reduce tetracycline absorption. Any food, fruit juice, tea or coffee can significantly reduce the absorption of bisphosphonates like alendronate and risedronate. Grapefruit juice is known to affect the absorption of a number of drugs including antihypertensives. Conversely, the presence of some foods may improve the absorption of a drug, for instance foods containing vitamin C help improve the absorption of iron.

**Effect of medication formulation on absorption**
The formulation of the medication affects drug absorption. Intravenous medicines bypass the absorption stage altogether, whilst intramuscular injections absorb gradually from the muscle tissue into the blood stream. Suppositories will absorb through blood vessels in the rectal wall and transdermal patches through the skin. Buccal and sublingual tablets which are designed to dissolve in the mouth are rapidly absorbed through the oral mucosa. Drug coatings and special modified release mechanisms also affect the rate of absorption (See Oral Medicines for more details).

**Drug distribution**
Once drugs have been administered and absorbed they are distributed into body tissues. The extent and pattern of distribution will be dependent mainly on the plasma and tissue protein binding characteristics of the drug and its lipid solubility (solubility in fatty tissues).

Drugs which are highly bound to plasma proteins (e.g. warfarin) distribute very little into the organs since bound drugs cannot cross the capillary membranes due to the large size of the protein molecules. When drugs do bind to plasma proteins, it is usually the proportion of the drug that remains unbound which has an active effect. Some drugs can displace others from their binding sites on the plasma proteins for example aspirin displaces warfarin from plasma proteins, leading to significant increases in the International Normalized Ratio (INR) in patients, as the higher level of free warfarin has a greater effect.

Highly lipid soluble drugs tend to concentrate in fat tissue and in the brain. Drugs that are highly water soluble may be confined to extracellular fluid since they will not easily diffuse across the high lipid containing cellular membranes. Some drugs are taken up actively into various tissues, particularly if they resemble a naturally occurring nutrient.

As the drug enters the bloodstream, the plasma level rises to a peak (the peak plasma level). The drug then starts to distribute itself around the body and drug metabolism starts.
Drug metabolism

Drug metabolism is the process by which the body chemically breaks down or changes a drug allowing eventual elimination from the body. Most metabolism takes place in the liver (hepatic metabolism), although it can occur in other areas of the body such as the intestines.

Some drugs which are known as pro-drugs are pharmacologically inactive until metabolised to the active form. An example is codeine which is metabolised to morphine by the body.

Drugs which are metabolised quickly have a short duration of action and need to be administered more frequently, whereas those which are metabolised more slowly will need less frequent administration. In general, as drugs are metabolised their therapeutic effect diminishes.

Some drugs undergo breakdown by first pass metabolism. They are absorbed through the stomach and small intestine after oral administration, and enter the portal circulation, which goes to the liver. They are then metabolised by liver enzymes before they have a chance to enter the systemic circulation. Buprenorphine and glyceryl trinitrate are examples of drugs which undergo extensive first pass metabolism. This is why they may be formulated for sublingual or transdermal administration to bypass this first pass metabolism effect, which would otherwise have rapidly rendered the active ingredient(s) inactive.

Liver enzymes - inducers and inhibitors

Some drugs known as enzyme inducers cause certain liver enzymes involved in the metabolism of drugs to work faster. Other drugs known as enzyme inhibitors reduce the action of certain liver enzymes resulting in the slow metabolism of some drugs.

This effect is of particular importance when one of these enzyme affecting drugs is started, stopped or the dose changed, as this may well affect the metabolism of some other medication being taken. One drug may alter the absorption, distribution, metabolism, or excretion of another, thus increasing or reducing the amount of drug available to produce its pharmacological effects. Whenever a medication is changed, the effect this may have on other medicines being taken should be considered.

Particular attention should be paid to patients who have illnesses impacting on liver function for example congestive heart failure, as reduced liver function may impair the ability to metabolise some drugs.

Drug excretion

Once drugs have had their desired effect, they need to be eliminated by the body.

Excretion predominantly occurs via renal elimination in the kidneys. Other elimination routes include excretion in bile, saliva, sweat, tears, faeces and exhaled air.

Plasma concentration

There are several terms associated with the plasma concentration of a drug.

Maximum concentration ($C_{max}$)

This is the highest concentration that a particular drug reaches in the blood stream and is sometimes referred to as the peak plasma concentration. The time taken to reach this level after taking a medicine is referred to as the $T_{max}$. In general the higher the $C_{max}$ the greater the risk of a patient developing dose-related side effects. To try to prevent a drug becoming toxic (a drug overdose) the frequency and dose of the drug need to be adjusted to ensure the $C_{max}$ does not exceed the toxic threshold.
Different types of oral formulations

Oral medicines are available in many different formulations including:
- Tablets
- Capsules
- Dispersible or effervescent tablets
- Sub-lingual tablets
- Buccal tablets and liquids
- Melts
- Oro-dispersible tablets
- Liquid medicines

Tablets and capsules

Tablets and capsules are the most commonly prescribed formulations of medicines, because they are convenient to use and provide a relatively stable environment for the drug. Tablets and capsules are made up of much more than just the active drug. They may also contain:
- Filling agents to provide bulk e.g. lactose, to which some people are intolerant
- Binders to hold the formulation together and possibly slow or delay drug absorption by slowing the break up of the tablet or capsule in the GI tract
- Disintegrants to help the dose break down quickly in the stomach to speed drug absorption
- Colourings to help identification
- Glidants to help during the manufacture of the tablet or capsule
- Surfactants to help drug absorption
- Flavourings to mask the taste
- Special coatings

Therapeutic window

The difference between the minimum plasma level for the drug to be clinically effective (therapeutic threshold) and the plasma level at which the drug becomes toxic is termed the ‘therapeutic window’ of the drug. The narrower the therapeutic window, the less margin there is between a drug being therapeutic and a drug being toxic or sub-therapeutic. For most drugs the therapeutic window is wide and occasional missed or additional doses may not affect the drug’s efficacy or safety.

However, a number of drugs have a narrow therapeutic window and even small changes in dose or metabolism can increase the likelihood of adverse effects or therapeutic failure.

Examples of drugs with a narrow therapeutic window include carbamazepine, phenytoin, lithium, warfarin, digoxin, gentamycin and vancomycin.

Minimum concentration \( (C_{\text{min}}) \)

This is the minimum concentration that a drug will reach in the blood stream between successive drug doses. This is important because if the \( C_{\text{min}} \) drops below the therapeutic threshold then the medication may no longer be effective. This would be termed under-dosing or sub-therapeutic dosing.

Plasma half life \( (T_{1/2}) \)

This is the time taken for the \( C_{\text{max}} \) of a drug to fall by half in the blood stream. It is a good indication of how quickly a particular drug is broken down and eliminated from the body. The longer the half life, the longer the drug will remain in the body.

Minimum concentration \( (C_{\text{min}}) \)

This is the minimum concentration that a drug will reach in the blood stream between successive drug doses. This is important because if the \( C_{\text{min}} \) drops below the therapeutic threshold then the medication may no longer be effective. This would be termed under-dosing or sub-therapeutic dosing.
73 year old Edith lived alone at home. When her GP reviewed her analgesia for arthritic joints, she said that her tramadol capsules (50mg) were giving some relief but she found it difficult to remember to take them four times a day. Often it was only the return of the pain that reminded her to take her medication. Ethel’s GP changed the prescription to tramadol 100mg MR tablets twice daily.

A week later Edith presented to the doctor with symptoms of nausea, dizziness and sweating. On examination her doctor could find no physical cause for these symptoms. Edith told her doctor that she seemed to feel worse an hour or two after breakfast and again in the evening. She also reported that she did not really like her new tablets as they were much harder to crush to take with her food - the swallows tablets or capsules had been much easier to open and mix with her meals. The side effects were a direct result of crushing the MR tablets.

Patients may sometimes crush or open capsules to make them easier to swallow without asking or informing any healthcare professional. To help prevent the potential risk of ADRs or poor clinical outcomes always ask patients if they are able to swallow tablets or capsules without manipulation.

**Different types of tablet coatings and modifications**

To reduce the frequency with which a drug needs to be taken and help improve patient compliance, drug delivery systems have become increasingly complex. Tablets and capsules may have special coatings for example ‘sugar coated’, ‘film coated’ or ‘enteric coated’ or they may be designed to modify the rate at which the drug is released into the body. It is important to understand the mechanism as well as the rationale before deciding whether it is safe or appropriate to crush tablets or open capsules.

**Film and sugar coating**

A sugar coating is a thick, hard coating of sugar surrounding the tablet inside which is used to hide the flavour of particularly unpleasant tasting drugs e.g. ibuprofen and quinine, both of which are extremely bitter.

Due to the large increase in the size of the tablet caused by sugar coating, film coatings now tend to be used instead. These are very thin layers of a safe ingredient placed around the tablet to again protect the tongue from the flavour of the contents and the contents from moisture. The film will however break down with a little agitation and significant amounts of moisture e.g. saliva or stomach acid and therefore does not significantly affect the way in which the drug is absorbed into the body.

Crushing these tablets therefore may not seriously affect how the drug is released but may cause the resultant mixture to be unpleasant to taste.

These tablets often have the letters s/c or f/c after the drug name. Sometimes the coating is not mentioned in the name at all.

**Enteric coating**

Enteric coated (e/c) tablets or capsules have a special coating on the outside that does not dissolve in acid. This means the drug is not released in the acid environment of the stomach but is released in the alkaline environment of the intestines. Examples of drugs which often have enteric coatings include prednisolone EC, gastro-resistant aspirin and lansoprazole capsules.

There are three reasons for putting such a coating on a tablet or capsule ingredient:
- To protect the stomach from the drug
- To protect the drug from the stomach acid
- To target the release of the drug after the stomach i.e. in the intestines

Enteric coated tablets should not be crushed before being taken as this will affect the efficacy of the medication and could cause patient harm.

**Modified release**

Drugs with a short half life need to be given frequently meaning that numerous doses may need to be taken over a 24 hour period. This can adversely affect patient compliance. For this reason drugs with a short half life are often formulated into modified release formulations, usually this is to slow the release of the drug over 12 or 24 hours.

Tablets and capsules which are designed to provide modified release often have the letters MR, LA, XL, CR or SR in their names e.g. nifedipine MR, isosorbide mononitrate LA, diltiazem XL. Sometimes the words ‘slow’ or ‘retard’ can be used to denote modified release e.g. Diclofenac retard, Voltarol retard & Slow K.

There are a number of ways in which a medicine can have its release modified:
- Embedding the drug in a matrix which releases the drug as it disintegrates
- Placing a lasered hole in the capsule/tablet coat as the only point of release. e.g. venlafaxine XL and nifedipine LA
- Placing the active drug into granules with coatings of different thicknesses which release at different rates
- Compressing the tablet so it takes longer to break up

The figure overleaf shows how a drug is theoretically released from a modified release formulation. The serum concentration does not spike so the risk of side effects is reduced and there is a prolonged period of time when the drug is active in the body.
In cases where a patient is unable to tolerate solid medication, then the advice of a doctor or pharmacist should be sought about suitable alternative formulations.

**Medication manipulation**

When a patient has difficulty swallowing a solid medicine, crushing tablets, opening capsules, dissolving/dispersing/suspending solid medicines not licensed or designed for use in this way, should never be undertaken unless there are specific, written instructions from the prescriber to do so or the Summary of Product Characteristics (SPC) states that this is how the medicine can be administered. See: www.medicines.org.uk/emc to access product SPCs.

The act of crushing tablets or opening capsules, which are not designed to be administered in this way, alters the formulation of the medication and potentially can have serious negative consequences for the patient. In particular, modified release drugs should always be swallowed whole (See above).

**Reasons not to manipulate medicines, unless specifically licensed for this purpose:**

1. A crushed tablet or opened capsule which is not designed for administration in this way is no longer a licensed product, making the prescriber and/or administrator and/or the person advising this practice legally liable if the patient suffers any harm as a result of the practice.
2. The rate or site of absorption may be affected, which could negatively impact on the effects of the medication.
3. Crushing medicines which are active over a small therapeutic window, such as digoxin, phenytoin, lithium and warfarin can change the rate of absorption of the active ingredient and could reduce efficacy and/or cause side effects.
4. Medicines which are enteric coated to prevent absorption in the stomach may be broken down in the stomach causing irritation or failure to reach the intended site of action.
5. Crushing a modified/slow release medication means that the patient may receive a large bolus very quickly, followed by a period of time when no active drug is being absorbed by the body.
6. Crushing of medicines which are coated to disguise the flavour of the drug, e.g. ibuprofen, quinine, will result in the patient receiving an unpalatable medicine, which could adversely impact on adherence to treatment.
7. A coating may prevent the administrator from suffering contact sensitisation, such as a skin rash from drugs such as chlorpromazine.
8. With any crushed tablet there is a risk of inhalation by the administrator and this is of greatest concern when hormonal or cytotoxic treatments are prescribed.
Liquid alternatives

If a patient has difficulty swallowing a solid medication, a liquid medicine may be more appropriate and easier to swallow. Many solid medications are available as licensed liquids, which means they have a Marketing Authorisation (MA) for use, issued by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA).

For products listed in the British National Formulary (BNF) or the Monthly Index of Medical Specialities (MIMS) for which there would appear to be no liquid version available, there are companies licensed to manufacture ‘special’ liquids. Pharmacists can advise on the availability of liquid alternatives.

Adverse drug reactions

An adverse drug reaction (ADR) is defined by the Medicines and Healthcare products Regulatory Agency (MHRA) as ‘an unwanted or harmful reaction experienced following the administration of a drug or combination of drugs under normal conditions of use, which is suspected to be related to the drug’. The reaction may be a known side effect of the drug or it may be new and previously unrecognised.

ADRs are common particularly amongst older patients. A study of ADRs as a cause of acute hospital admission in patients over 75 years found:

- 30% of acute admissions may have been due to ADRs
- 53% of the ADRs were preventable
- 48% were caused by cardiovascular drugs
- 26% were due to non-compliance with medication
- The most common manifestations of ADRs were falls, postural hypotension, heart failure and delirium

Type A reactions

Type A (augmented) reactions result from an exaggeration of a drug’s normal pharmacological actions when given at the usual therapeutic dose and are normally dose-dependent.

Examples include:
- Low blood pressure with antihypertensives
- Low blood sugar with insulin

Type A reactions also include those that are not directly related to the desired pharmacological action of the drug (e.g. dry mouth that is associated with tricyclic antidepressants).

Type B reactions

Type B (bizarre) reactions are novel responses that are not expected from the known pharmacological actions of the drug, for example:
- Anaphylaxis with penicillin
- Skin rashes with antibiotics
When to report an ADR

Do you suspect an ADR?
- Yes 
  - Is it a serious reaction?
    - Yes 
      - Report
    - No 
      - Is the patient a child?
        - Yes 
          - Report
        - No 
          - Are you unsure whether to report?
            - Yes 
              - Report

For further information about reporting an ADR, visit: www.mhra.gov.uk

Common medication causes of adverse drug reactions in older people
Pharmacokinetic, pharmacodynamic and physiological changes which result from ageing contribute to an increased sensitivity to drugs and adverse drug reactions in older people.

The most common causative drugs of ADRs in older patients are cardiovascular drugs. See chart on next page.

Reporting ADRs
The MHRA recommends that a Yellow Card is completed if there is a suspicion that a drug has caused an adverse reaction. See: http://yellowcard.mhra.gov.uk

All suspected adverse reactions which are considered to be serious should be reported through the Yellow Card system. The MHRA defines serious reactions as those which are:
- fatal
- life-threatening
- disabling
- incapacitating
- have resulted in, or prolonged hospitalisation
- medically significant
- caused congenital abnormalities
- noxious and unintended

The MHRA are particularly interested in receiving reports about adverse reactions in older people, who may be more susceptible to developing reactions as they tend to metabolise medicines less effectively, and be more sensitive to their effects. Therefore, they may be more susceptible to developing reactions. The MHRA now regards reports direct from patients as valid. Their definition of an ADR has been extended to include all reports where harm has occurred to a patient. This will mean that ADRs that are a result of error, misuse and where used off-label should be reported.
Common medication causes of adverse drug reactions in older people - cardiovascular system

ACE inhibitors need to be given with care to patients receiving diuretics. First doses can cause hypotension especially in patients taking high doses of diuretics. They can cause a very rapid fall in blood pressure and close observation is recommended after administration of the first dose of ACE inhibitor, for at least 2 hours or until the blood pressure has stabilised.13

Beta blockers slow the heart and can depress the myocardium. They can affect carbohydrate metabolism, causing hypoglycaemia or hyperglycaemia in patients with or without diabetes.13

Calcium channel blockers (calcium antagonists) can cause hypotension, but different drugs in this category have different sites of action, with different therapeutic effects and side effects.13

Digoxin The level of potassium in the body has a significant effect on the toxicity of digoxin. Low potassium (hypokalaemia) is a major cause of digoxin toxicity. Signs of digoxin toxicity include:
• Nausea/vomiting
• Dizziness
• Visual disturbance
• Cardiac arrhythmia

Diuretics side effects relate directly to the action of the diuretic:

Loop diuretics such as furosemide produce a fast onset of diuresis (usually complete within six hours) which may lead to:
• Urinary incontinence
• Acute retention

If taken on an empty stomach, diuresis is more rapid in onset and shorter in duration. Doses may be split to give a more gradual diuresis.

Thiazides like bendroflumethiazide have a more prolonged diuresis than loop diuretics (around 12 hours).

Both groups of diuretics cause potassium and sodium depletion, which may cause retention of uric acid leading to gout. The changes in salt balance can lead to potential reactions with other medications. Loop and thiazide diuretics

Clinical presentation of ADRs in older people

Adverse drug reactions often present in older patients in a non-specific way. Common manifestations of ADRs include confusion (caused by almost any of the most commonly prescribed drugs), constipation (with antimuscarinics and many tranquillisers), postural hypotension and falls (with diuretics and many psychotropics).13

The most common presentations of ADRs in older patients are listed below11:
• Falls
• Pulmonary oedema/heart failure
• Delirium
• Acute renal failure
• Stroke
• Palpitations
• Angina
• Bradycardia
• Nausea and vomiting
• Hyper/hypoglycaemia
• Seizure
• Parkinsonism

Clinical presentation of ADRs in older people - continued

Adverse drug reactions often present in older patients in a non-specific way. Common manifestations of ADRs include confusion (caused by almost any of the most commonly prescribed drugs), constipation (with antimuscarinics and many tranquillisers), postural hypotension and falls (with diuretics and many psychotropics).13

The most common presentations of ADRs in older patients are listed below11:
• Falls
• Pulmonary oedema/heart failure
• Delirium
• Acute renal failure
• Stroke
• Palpitations
• Angina
• Bradycardia
• Nausea and vomiting
• Hyper/hypoglycaemia
• Seizure
• Parkinsonism

Adverse drug reactions (Continued)

<table>
<thead>
<tr>
<th>Medication group</th>
<th>Drug class</th>
<th>% drugs causing ADR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular</td>
<td>ACE-Inhibitor</td>
<td>13.9%</td>
</tr>
<tr>
<td></td>
<td>Diuretics</td>
<td>10.7%</td>
</tr>
<tr>
<td></td>
<td>Beta-blockers</td>
<td>7.4%</td>
</tr>
<tr>
<td></td>
<td>Calcium antagonists</td>
<td>6.6%</td>
</tr>
<tr>
<td></td>
<td>Digoxin</td>
<td>4.9%</td>
</tr>
<tr>
<td></td>
<td>Nitrates</td>
<td>4.9%</td>
</tr>
<tr>
<td>Total cardiovascular ADR %</td>
<td>48.4%</td>
<td></td>
</tr>
<tr>
<td>CNS</td>
<td>Antidepressants</td>
<td>7.4%</td>
</tr>
<tr>
<td></td>
<td>Benzodiazepines</td>
<td>4.9%</td>
</tr>
<tr>
<td></td>
<td>Phenothiazines</td>
<td>4.9%</td>
</tr>
<tr>
<td></td>
<td>Antiparkinsonian</td>
<td>2.5%</td>
</tr>
<tr>
<td></td>
<td>Anti-epileptics</td>
<td>0.8%</td>
</tr>
<tr>
<td>Total CNS ADR %</td>
<td>20.5%</td>
<td></td>
</tr>
<tr>
<td>Anti-inflammatories</td>
<td>Corticosteroids</td>
<td>5.7%</td>
</tr>
<tr>
<td></td>
<td>NSAIDs</td>
<td>4.9%</td>
</tr>
<tr>
<td>Total anti-inflammatories ADR %</td>
<td>10.6%</td>
<td></td>
</tr>
<tr>
<td>Anti-thrombotics</td>
<td>Aspirin</td>
<td>4.1%</td>
</tr>
<tr>
<td></td>
<td>Warfarin</td>
<td>1.6%</td>
</tr>
<tr>
<td>Total anti-thrombotics ADR %</td>
<td>5.7%</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td></td>
<td>15.6%</td>
</tr>
</tbody>
</table>

Adapted from Chan M, Nicklason F and Vial JH11
are often combined with a potassium sparing diuretic such as spironolactone or amiloride to try to stabilise potassium levels.\textsuperscript{13}

**Common medication causes of adverse drug reactions in older people - central nervous system (CNS)**

**Hypnotics and sedatives:** Many hypnotics with long half-lives have serious hangover effects; including drowsiness, unsteady gait, slurred speech and confusion.\textsuperscript{13}

Benzodiazepines are the most commonly used anxiolytics and hypnotics. A paradoxical increase in hostility and aggression may be reported by patients taking benzodiazepines. The effects range from talkativeness and excitement to aggressive and antisocial acts. Increased anxiety and perceptual disorders are other paradoxical effects. Benzodiazepines impair balance, which can result in falls.\textsuperscript{13}

Withdrawal of a benzodiazepine should be gradual because abrupt withdrawal may produce confusion, toxic psychosis, convulsions, or a condition resembling delirium tremens.\textsuperscript{13}

**Tricyclic antidepressants:** All tricyclic drugs including amitriptyline, imipramine and lofepramine can cause drowsiness, confusion, postural hypotension and anticholinergic side effects: drowsiness, dry mouth, blurred vision, constipation and urinary retention. They also interfere with body temperature regulation so regular temperature records are important for elderly people prescribed these drugs.

The BNF recommends that as ‘Elderly patients are particularly susceptible to many of the side-effects of tricyclic antidepressants; low initial doses should be used, with close monitoring, particularly for psychiatric and cardiac side-effects’.

Tricyclic and related antidepressant drugs should be used with caution in patients with cardiovascular disease because of the risk of arrhythmias.\textsuperscript{13}

**Lithium:** Altered pharmacokinetics in the elderly often prolongs the half-life of lithium, so caution must be exercised to avoid toxicity, particularly as lithium has a narrow therapeutic window. Toxic effects include tremor, ataxia, dysarthria, nystagmus, renal impairment and convulsions.\textsuperscript{13}

**Note:** Low sodium levels (hyponatraemia) have been associated with all types of antidepressants and should be considered in patients who develop drowsiness, confusion or convulsions while taking an antidepressant.

**Neuroleptic (antipsychotic) drugs** commonly prescribed for older people include phenothiazines like chlorpromazine and trifluoperazine; and butyrophenones like haloperidol. They are likely to cause drowsiness, hypotension, constipation and impaired temperature control. The use of phenothiazines can sometimes cause seizures. Extrapyramidal (antidopaminergic) side effects are common. These include:

- Parkinsonism
- Dystonia (abnormal face and body movements) which may appear after only a few doses
- Akathisia (restlessness) which may resemble an exacerbation of the condition being treated
- Tardive dyskinesia (involuntary movement) which may appear after a longer period

Antipsychotics can increase the risk of stroke in older people with dementia and in any patient with pre-existing risk factors.\textsuperscript{14}

**Common medication causes of adverse drug reactions in older people - anti-inflammatory drugs**

Bleeding associated with aspirin and other NSAIDs (non-steroidal anti-inflammatory drugs) is more common in older people who are more likely to have a fatal or serious outcome. NSAIDs are also a special hazard in patients with cardiac disease or renal impairment which may again place older patients at particular risk.\textsuperscript{13}

\textsuperscript{25} patients in 55 homes on a mean of 8 medicines each were studied. 69.5% of patients experienced at least one medication error. 39.1% received a prescribing error, 18.4% a monitoring error, 36.7% a dispensing error and 22.3% an administration error.

The report concluded: There is an unacceptable prevalence of medication errors in care homes, affecting some of the most vulnerable members of society. Action is required from all concerned.\textsuperscript{15}
Polypharmacy and cascade prescribing

Increasing age is associated with multiple co-morbidities, which means that older people receive more prescribed medicines to treat a number of conditions. The prescription of four or more medicines is known as polypharmacy. Although it might be appropriate to prescribe numerous medications for a patient there is a risk of cascade prescribing, where side effects from one drug result in a new drug being added to treat the effects, e.g. prescribing prochlorperazine for patients with digoxin induced nausea. Another example would be a treatment with a non-steroidal anti-inflammatory drug leading to a rise in blood pressure, with a subsequent prescription of an antihypertensive drug.

To ensure that a new prescription is not being initiated to treat the side effects of another drug, it is necessary to differentiate adverse drug reactions from underlying pathology. This is particularly true of the four conditions below which are common in older patients:

- **Incontinence** - may be caused by medication, infection, decreased mobility or a range of disease states e.g. benign prostatic hypertrophy
- **Intellectual impairment** - caused by medication and a number of diseases including dementia
- **Instability** - caused by medication, postural hypotension or visual impairment
- **Immobility** - caused by instability, previous falls and diseases such as arthritis

Whenever an older person presents with one of the above conditions it is necessary to review the medications being prescribed in relation to the physiological changes associated with ageing.

STOPP and START criteria

The STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions) and START (Screening Tool to Alert to Right Treatment) criteria have been designed and validated to help improve medication management in older people.

The STOPP screening tool

STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions) is a medicine review tool comprising of 65 clinically significant criteria for potentially inappropriate prescribing in older people. The aim is to identify drugs which should be avoided in older people because the risks often outweigh the benefits.

STOPP criteria identified at least one potentially inappropriate medication in 35% of older patients requiring admission to hospital.

Examples from STOPP include:
- Potentially inappropriate prescription of NSAIDs e.g. in people with peptic ulcer disease, heart failure, hypertension
- Patients with a history of falls receiving potentially inappropriate psychoactive medications like long-acting benzodiazepines
- Patients with an isolated fall inappropriately prescribed sedating antihistamines and opiates

The START screening tool

The START screening tool (Screening Tool to Alert to Right Treatment) was designed and validated for identifying prescribing omissions in older adults. Using the START list, one or more prescribing omissions in 57.9% of patients were identified. In order of prevalence, the most common prescribing omissions were:

- **Statins in atherosclerotic disease** (26%)
- **Warfarin in chronic atrial fibrillation** (9.5%)
- **Anti-platelet therapy in arterial disease** (7.3%)
- **Calcium/vitamin D supplementation in symptomatic osteoporosis** (6%) 17

Medication review

As people get older, their use of medicines tends to increase. Four in five people over 75 take at least one prescribed medicine, and 36% take four or more medicines. All people over 75 years should have their medicines reviewed at least annually and those taking four or more medicines should have a 6 monthly review.

Ensure that directions about how to take medication have always been fully understood.

An 80 year old lady, living at home was prescribed Slo-Phyllin capsules to help her breathing difficulties. She was advised not to break open the capsules but to swallow them whole. She understood this to mean that she should not pop the capsules out of the blister pack. She cut round each blister and swallowed both the capsule and blister. She was admitted to hospital with an intestinal obstruction.

Multiple diseases and complicated medication regimes may affect a patient’s capacity and ability to manage their own medication. Appropriate prescribing for older people and monitoring of their condition are key objectives set out in the NSF for Older People. However, it is not only the medicines prescribed but also how the medicines are actually used by patients that should be considered. The lifestyle and physical needs of the patient need to be taken into consideration.
Community pharmacists offer a Medicines Use Review (MUR) service which is a planned face-to-face consultation between a pharmacist and a patient to discuss their medicines. The review is concordance-centred and aims to help increase the patients’ knowledge and understanding of their medicines, including how and why they should be taken. It also provides an opportunity to highlight any concordance issues, side effects or other medicine-related problems from the patient’s perspective and propose solutions if appropriate.

Prescribing for older people

Older patients require special care and consideration from prescribers. Medicines for Older People, a component document of the National Service Framework for Older People describes how to maximise the benefits of medicines and how to avoid excessive, inappropriate, or inadequate consumption of medicines by older people.

Appropriate prescribing

Elderly patients often receive multiple drugs for their multiple diseases. This greatly increases the risk of drug interactions as well as adverse reactions, and may affect compliance. The balance of benefit and risk of some medicines may be altered in older people. Therefore, older patients’ medicines should be reviewed regularly and medicines which are not of benefit should be stopped.

Formulation of the medicine

Older patients may have difficulty swallowing tablets; if left in the mouth, ulceration may develop. They should always be encouraged to take their tablets or capsules with enough fluid, and whilst in an upright position, or be prescribed the medication in a liquid format instead.

Manifestations of ageing

In the very old, manifestations of normal ageing may be mistaken for disease and lead to inappropriate prescribing. In addition, age-related muscle weakness and difficulty in maintaining balance should not be confused with neurological disease. Disorders such as lightheadedness not associated with postural or postprandial hypotension, are unlikely to be helped by drugs.

Sensitivity

The nervous system of older patients is more sensitive to many commonly used drugs, such as opioid analgesics, benzodiazepines, antipsychotics, and antiparkinsonian drugs, all of which must be used with caution. Similarly, other organs may also be more susceptible to the effects of drugs such as antihypertensives and NSAIDs.

**Principles of medication management and older people**

The following basic principles will help ensure that an older person receives appropriate treatment with the most appropriate medication to optimise their health and well-being.9

- Limit the range of drugs used so that you are familiar with them
- Consider starting any new drugs at half the usual adult dose and avoiding any drugs where potential risks outweigh possible benefits
- Review medication regularly - ensure there is an indication and therapeutic goal for all prescribed drugs. Stop any that are no longer required. Monitor renal function and alter dosages as necessary
- Simplify regimes - try to choose medicines which only require once or twice a day dosing intervals
- Explain any changes to medication clearly and ensure prescriptions contain full dosing instructions
- Explain what to do when the patient has finished their medication, including what to do with stocks of medicine that have been discontinued
- If you believe that the patient is not coping despite the above measures think about enrolling the help of a relative or friend
Factors affecting adherence

It is estimated that up to 50% of patients do not take their medication as prescribed and reports of unused or wasted medications exceed £100m every year. Several factors have been implicated in non-adherence and considering these factors and discussing where appropriate with the patient is the best approach to minimise non-adherence.

**Difficulty accessing medication from packaging** - it may be difficult for an older person with for example arthritis to unscrew a cap or remove tablets from a blister pack. Child-resistant containers may pose particular difficulties.

**Sight impairment** - this will affect a person’s ability to distinguish between their medicines, read container labels and access medication from packaging.

**Dysphagia** - swallowing difficulties may impair a patient’s ability to adhere to prescribed medicines. The most frequently reported problem is the size of oral solid dosage forms.

**Confusion/forgetfulness and advancing age** - forgetfulness is often given as a reason for non-adherence.

**Treatment regimen** - research shows a progressive decline in adherence with an increasing number of medications prescribed. Simplifying dosing to once or twice daily may help.
Licensed and unlicensed medicines

Before a medicine can be sold in the UK, a product must have a licence called a ‘marketing authorisation’ (formerly known as a ‘product licence’). The use of licensed medicines maximises patient safety while minimising liability, but there are occasions when an unlicensed or off-label medicine is prescribed and dispensed. This may be because:

- It is an unusual formulation or strength
- It may be a preservative or additive-free product
- For some diseases there are no licensed medicines
- It might be prescribed for a disease or a type of patient outside of the drug’s Marketing Authorisation

An ‘off-label’ medicine is a licensed medicine which is used outside its licence. For example a medicine might have a licence for one condition, but may be prescribed for a different condition.

Medicines and the regulatory framework

Medication is a key element of patient care and all professionals who are involved in medicines management are governed by a legal and professional accountability to follow best practice when prescribing and administering medication. A strict legal framework regulates the supply, prescription and administration of medicines to protect patient safety.

In summary, the law requires that the:
- Right medicine is given to the:
- Right patient, at the
- Right time, using the
- Right dose, in the
- Right formulation

The following is a summary of some of the laws and professional codes of conduct which govern the prescription and administration of medicines in the UK.

The Human Medicines Regulations 2012

The Human Medicines Regulations 2012 regulates the licensing, supply and administration of medicines. Medicines must be used in line with the marketing authorisation (MA) abbreviated in the summary of product characteristics (SPC) supplied by the manufacturer. If the dose, route of administration or form of the medicine is changed from that set out in the SPC for example, by crushing a tablet not licensed to be given in this way, this would be a breach of the 2012 Regulations. If any harm arose to the patient as a result, the person manipulating the medicine would be held legally liable.

Health and Social Care Act 2008 and the Care Quality Commission (CQC)

This Act created a new regulator, the Care Quality Commission (CQC) and all providers of health and adult social care services need to register with the Commission which has the authority to impose essential standards for quality and safety.

Managing medicines is a regulated activity under this Act and healthcare professionals have a duty to protect patients against risks associated with the management of medicines. The Act requires that:

‘The registered person must protect service users against the risks associated with the unsafe use and management of medicines, by means of the making of appropriate arrangements for the obtaining, recording, handling, using, safe keeping, dispensing, safe administration and disposal of medicines used for the purposes of the regulated activity.’

Medicines provided to service users should be appropriate and person-centred, taking into account the age, preferences, lifestyle, condition and disabilities of the patient. The most appropriate medicine, route and form of the drug should be considered in each patient’s case. The CQC also requires that all prescriptions be up to date, reviewed and changed as the service user’s needs change.

The CQC works with professional regulatory bodies, including the General Medical Council and the Nursing & Midwifery Council (NMC) and will pass on evidence of poor practice to the relevant regulator for investigation of fitness to practise.

Equality Act 2010

Medication management must comply with the requirements of the Equality Act 2010. This law gives people with disability the same right to access services as an able-bodied person, and it is unlawful to discriminate against a person because of their disability. This includes the right of access to, and benefit from, medicinal products. Providing disabled service users with support to manage and take medicine safely is a duty under the Act. It may be necessary to request the changing of a bottle top to a non-safety version, or remove tablets from blister packs into a bottle for a person with arthritis. Patients with visual impairment can have large-print labels, and the outer packaging of medicines must now have the name of the drug in Braille.
People with complex medicine regimens or who are forgetful may be given medication administration records to help manage their medicines and, where further assistance is required, pharmacists may provide monitored dosing systems for the patient.

Swallowing difficulties may affect a patient’s ability to take the prescribed medication and these patients will need particular management if medication compliance is to be achieved. Most commonly prescribed medicines are available in liquid form, which can make swallowing easier.\(^9\)

**The Nursing & Midwifery Council (2008)**  
**Standards for Medicines Management**  
The Nursing & Midwifery Council (NMC) has issued standards (2008) for medicines management that remind nurses that they have a responsibility to deliver safe and effective care based on current evidence and best practice. The NMC recognises the importance of medicines and states:

> ‘The administration of medicines is an important aspect of the professional practice of persons whose names are on the Council’s register. It is not solely a mechanistic task to be performed in strict compliance with the written prescription of a medical practitioner (can now also be an independent and supplementary prescriber). It requires thought and the exercise of professional judgement...’

Minimum standards are set for safe practice in the management and administration of medicines and reflect the process from prescribing through to dispensing, storage, administration and disposal.

The NMC has also issued advice about tablet crushing, stating that:

> “The mechanics of crushing medicines may alter their therapeutic properties rendering them ineffective and are not covered by their product licence. Medicinal products should not routinely be crushed unless a pharmacist advises that the medication is not compromised by crushing, and crushing has been determined to be within the patient’s best interest.”\(^20\)

**Patient consent**  
Even though an appropriately qualified healthcare professional has the right to prescribe a medicine, the medicine can only be given to the person with their consent. A patient has a right to refuse medication (however unreasonably) and those caring for the patient must respect that right.

‘It is established that the principle of self-determination requires that respect must be given to the wishes of the patient, so that if an adult patient of sound mind refuses, however unreasonably, to consent to treatment or care [those] responsible for his care must give effect to his wishes, even though they do not consider it to be in his best interests to do so.’\(^9\)

However, the right to decide presupposes the mental capacity to do so. Every adult is presumed to have this capacity unless this can be rebutted under the Mental Capacity Act 2005. The Act states that a person lacks capacity if some impairment or disturbance of mental functioning renders the person unable to make a decision whether to consent to or refuse treatment.\(^9\)

**Negligence**  
The law of negligence places a duty of care on healthcare professionals to prescribe and administer medication to patients to a standard consistent with a responsible body of professional opinion. If harm is caused as a result of breaching a duty of care then there will be liability in negligence.

The duty of care extends to advice giving, diagnosis, treatment and prescribing practice. If a healthcare professional recommended that medication is crushed or a capsule opened to assist a person with a swallowing difficulty and harm results then liability in negligence would arise.

In the event of a negligence case being brought with regard to tablet crushing, the court would consider whether:

- There were alternative products available such as liquid preparations, including ‘specials’.  
- The prescriber gave approval for crushing  
- The pharmacist was consulted about the safety of crushing the tablet  
- The person was told about the risks involved and gave consent or a determination of best interests was made  
- A respected body of professional opinion would have crushed the medication in the same circumstances  
- The evidence stands up to logical analysis

The practice of crushing tablets and opening capsules is one that has the potential to endanger public safety and thereby breach the legal and professional requirements. It must not be done when there is a safer alternative such as a liquid preparation.\(^9\)
Absorption
the process of how the medicine enters the body (blood and other organs).

Adverse drug reaction
an unwanted or harmful reaction experienced following the administration of a drug or combination of drugs under normal conditions of use, which is suspected to be related to the drug.

Akathisia
a movement disorder characterized by a feeling of inner restlessness and a compelling need to be in constant motion. Is often a side effect of certain drugs.

Anxiolytic
a type of drug which is used to treat anxiety.

Arrhythmias
the deviations from the normal rhythm of the heart.

Ataxia
lack of voluntary coordination of muscle movements, e.g. as in walking.

Blood-brain barrier
the semi-permeable membrane which keeps circulating blood separate from the cerebral-spinal fluid surrounding the brain.

Cascade prescribing
the prescribing of a second drug to treat the side effects of a first.

Cellular membrane
the membrane that surrounds each cell. It contains a high level of fats called lipids.

Delirium
an acute confusional state.

Distribution
where the medicine is distributed around the body after the drug has been absorbed.

Diuresis
the production of urine.

Dysarthria
a motor speech disorder.

Dysphagia
the medical term for the symptom of difficulty in swallowing.

Dystonia
abnormal face and body movements.

Elimination
the routes by which the drug or the metabolites of the drug leave the body. Also known as excretion.

EMA
the European Medicines Agency, which is
<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Licensed product</td>
<td>a medicinal product that has a Marketing Authorisation. Its use is stipulated in its Summary of Product Characteristics.</td>
</tr>
<tr>
<td>Marketing Authorisation</td>
<td>medicines which meet the MHRA’s standards of safety, quality and efficacy are granted a marketing authorisation (previously a product licence).</td>
</tr>
<tr>
<td>Medication manipulation</td>
<td>the act of crushing a tablet, opening a capsule, dissolving or “melting” a tablet or capsule content.</td>
</tr>
<tr>
<td>Metabolism</td>
<td>is the mechanism by which the drug is broken down by the body usually undertaken by enzymes in the liver. Some drugs are designed to only become active after they have been metabolised. These are called &quot;pro-drugs&quot;.</td>
</tr>
<tr>
<td>MHRA</td>
<td>the Medicines and Healthcare products Regulatory Agency (MHRA) is the government agency which is responsible for ensuring that medicines and medical devices are effective, and are acceptably safe.</td>
</tr>
<tr>
<td>Modified release</td>
<td>tablets or capsules that have a mechanism to prolong the release of the drug over a longer period of time. Also known as slow release.</td>
</tr>
<tr>
<td>Myocardium</td>
<td>the muscle of the heart.</td>
</tr>
<tr>
<td>Nystagmus</td>
<td>a condition of involuntary eye movement.</td>
</tr>
<tr>
<td>Paradoxical excitement</td>
<td>agitation caused by administration of a sedative,</td>
</tr>
<tr>
<td>Peak plasma concentration</td>
<td>the highest concentration that a drug reaches in the blood.</td>
</tr>
<tr>
<td>Pharmacodynamics</td>
<td>the study of the biochemical and physiological effects of drugs on the body and the mechanisms of drug action and the relationship between drug concentration and effect it exerts.</td>
</tr>
<tr>
<td>Pharmacokinetics</td>
<td>the study of the mechanisms of absorption and distribution of an administered drug, the rate at which a drug action begins and the duration of the effect, the chemical changes of the substance in the body (e.g. by metabolic enzymes) and the</td>
</tr>
</tbody>
</table>


4. Department of Health, Medicines and Older People: Implementing medicines-related aspects of the NSF for Older People, March 2001


**Glossary of terminology (Continued)**

- **Plasma proteins**: proteins in the plasma which can bind with some drugs.
- **Plasma protein binding**: the extent to which drugs are bound to proteins in the plasma which affects their level of activity and the extent to which they are distributed round the body.
- **Polypharmacy**: multiple drug prescribing.
- **Postural hypotension**: a rapid onset of low blood pressure due to standing or stretching too quickly.
- **Pro-drug**: a drug that is administered in an inactive form, which becomes active following metabolism within the body.
- **Renal**: concerning the kidneys.
- **Renal clearance**: the rate at which waste products are eliminated from the body by the kidneys.
- **Renal function**: a measure of how well the kidneys are working.
- **Slow release**: tablets or capsules that have a mechanism to prolong the release of the drug over a longer period of time. Also known as modified release.
- **Solid medication**: a tablet or capsule.
- **Sub-therapeutic**: below the dose required to have a medicinally beneficial effect.
- **Tardive dyskinesia**: neurological disorder of involuntary movements usually caused by long-term use of antipsychotic or neuroleptic drugs.
- **Therapeutic window**: the difference between the minimum plasma level for the drug to be clinically effective and the plasma level at which the drug becomes toxic.
- **Xerostomia**: dryness of the mouth, due to reduced saliva production.
Ralph S. Greenwall, BPharm (Hons)

Ralph first registered as a pharmacist in 1990. He has worked extensively with care homes as a community pharmacist, a care home owner, and as the pharmaceutical advisor to a national care home provider. He has developed a keen interest in the management of medication in older people particularly in the areas of compliance and concordance. Over the years Ralph has been involved in numerous projects to develop and improve this field of care.

Ralph says: “The safe delivery of medicines for older people is a critical and challenging aspect of care. It is complicated by multiple diseases, complex medication regimes and the ageing process affecting the body’s capacity to handle medicines. In addition, medicines have become increasingly sophisticated, particularly in their delivery systems and there are legal aspects to consider as well as pharmacological ones. This new guide aims to help healthcare professionals deliver the best possible medication care for their patients and residents.”
For further free copies of this booklet, please contact
Roosemont Pharmaceuticals:
Tel: +44 (0)113 244 1999
Email: marketing@roosemontpharma.com
www.roosemontpharma.com

The source of liquid solutions.

An educational support booklet sponsored by
Roosemont Pharmaceuticals